FDA approves voclosporin for adults with active lupus nephritis

Approval of this ciclosporin analogue is based on data from the AURORA phase III RCT (n=357) which demonstrated improved complete renal response rates in addition to standard care vs standard care alone at 52 weeks (n=357; 40.8% vs 22.5%; OR 2.65; 95% CI 1.64-4.27; P<0.001),

Biospace Inc.